3.02

0.33% 0.01

After Hours: 3.01 -0.01 -0.33%

Pyxis Oncology Inc (PYXS)

Overview News Price History Option Chain Financials Why PYXS Down? Discussions Forecast

Pyxis Oncology Inc stock is traded at $3.02, with a volume of 557.56K. It is up +0.33% in the last 24 hours and up +27.97% over the past month. Pyxis Oncology Inc is a clinical-stage oncology company focused on developing therapies for patients with solid tumors, with an initial emphasis on head and neck squamous cell carcinoma. Its product candidate, micvotabart pelidotin (MICVO, formerly PYX-201), is an investigational antibody-drug conjugate that targets extradomain-B fibronectin (EDB+FN), a component of the tumor extracellular matrix that is expressed in tumors and minimally present in normal tissues. MICVO consists of a fully human monoclonal antibody linked to a microtubule inhibitor payload, designed to bind within the tumor microenvironment and release its payload to kill cancer cells directly, affect nearby cells through a bystander effect, and induce immunogenic cell death, supporting enhanced anti-tumor activity.

Previous Close:

$3.01

Open:

$3.03

24h Volume:

557.56K

Relative Volume:

0.48

Market Cap:

$251.89M

Revenue:

$13.86M

Net Income/Loss:

$-81.74M

P/E Ratio:

-2.3167

EPS:

-1.3036

Net Cash Flow:

$-66.98M

1W Performance:

-21.15%

1M Performance:

+27.97%

6M Performance:

+127.07%

1Y Performance:

+145.53%

1-Day Range:

$2.83

$3.09

1-Week Range:

$1.90

$4.00

52-Week Range:

$1.03

$5.55

Pyxis Oncology Inc Stock (PYXS) Company Profile

Name

Pyxis Oncology Inc

Sector

Healthcare (1082)

Industry

Biotechnology (606)

Phone

(617) 221-9059

Address

321 HARRISON AVENUE, BOSTON

Employee

Twitter

Next Earnings Date

2026-08-13

Latest SEC Filings

PYXS's Discussions on Twitter

Compare PYXS vs VRTX, REGN, ARGX, RVMD, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PYXS Pyxis Oncology Inc	3.02	251.06M	13.86M	-81.74M	-66.98M	-1.3036
VRTX Vertex Pharmaceuticals Inc	515.55	128.19B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	805.93	82.72B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	987.84	53.26B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	212.00	43.66B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	362.51	39.31B	5.76B	514.49M	1.10B	4.4813

Pyxis Oncology Inc Stock (PYXS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Nov-03-25	Resumed	Stifel	Buy
Sep-04-25	Initiated	Guggenheim	Buy
Nov-21-24	Downgrade	William Blair	Outperform → Mkt Perform
Nov-08-24	Initiated	Stephens	Overweight
Aug-08-24	Initiated	Stifel	Buy
May-07-24	Resumed	Jefferies	Buy
Feb-09-24	Initiated	BTIG Research	Buy
Jan-23-24	Initiated	Leerink Partners	Outperform
Sep-05-23	Initiated	RBC Capital Mkts	Outperform
Nov-02-21	Initiated	BofA Securities	Neutral
Nov-02-21	Initiated	Credit Suisse	Outperform
Nov-02-21	Initiated	Jefferies	Buy

View All

Pyxis Oncology Inc Stock (PYXS) Latest News

Aug 15, 2026

Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Aug 15, 2026

Aug 14, 2026

Pyxis Oncology (PYXS) CEO receives 250,956-share performance-based option grant - Stock Titan

Aug 14, 2026

Pyxis Oncology Inc (NASDAQ: PYXS) Share Price, PYXS Stock News, PYXS Share Price & Updates - Kalkine

Aug 14, 2026

LifeSci Capital Maintains Pyxis Oncology(PYXS.US) With Buy Rating, Maintains Target Price $6 - Moomoo

Aug 14, 2026

Pyxis Oncology Faces Mounting Dilution Risk as Ongoing Equity Raises and Warrants Pressure Shareholder Value - TipRanks

Aug 14, 2026

Aug 13, 2026

Pyxis Oncology (NASDAQ:PYXS) Releases Quarterly Earnings Results, Misses Expectations By $0.06 EPS - MarketBeat

Aug 13, 2026

Pyxis Oncology Releases Q2 2026 Financial Results - news.alphastreet.com

Aug 13, 2026

Pyxis Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026

Pyxis Oncology Q2 loss widens 38%, misses EPS estimate - scanx.trade

Aug 13, 2026

Form 8K Pyxis Oncology Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026

PYXS: MICVO demonstrates high efficacy and disease control in R/M HNSCC, with pivotal data due in 2026 - TradingView

Aug 13, 2026

Pyxis Oncology, Inc. Q2 2026: Revenue $0 EPS $(0.40) — 10-Q Summary - TradingView

Aug 13, 2026

Pyxis Oncology Reports $25.3 Million Second-Quarter Net Loss - Quiver Quantitative

Aug 13, 2026

Pyxis Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 13, 2026

Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones - The Manila Times

Aug 13, 2026

Pyxis Oncology 2Q Research and Development Expenses $16.1M >PYXS - Moomoo

Aug 13, 2026

Pyxis Oncology expects two MICVO cancer-study data updates in 2026 - Stock Titan

Aug 13, 2026

Aug 12, 2026

currently "more than watching" heheheh - Moomoo

Aug 12, 2026

Aug 10, 2026

Pyxis Oncology Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView

Aug 10, 2026

Aug 09, 2026